Press Releases

Date News
September 19, 2017 Sunshine Biopharma Annouces The Terms Of Its Brokered Up To $10 Million In Private Placement Financing
September 5, 2017 Sunshine Biopharma Enters Into An Investment Banking Agreement With Jitney Trade To Raise Up To $10 Million For Clinical Trials Of Adva-27a Anticancer Drug
June 26, 2017 Sunshine Biopharma Releases Results of Independent Valuation
June 19, 2017 Sunshine Biopharma Files An Application With Health Canada For A Drug Establishment License
January 11, 2017 Sunshine Biopharma Currently Reviewing Twenty Three Additional Generic Products For In-licensing
December 9, 2016 Sunshine Biopharma Signs Strategic Alliance Agreement With Atlas Pharma
June 30, 2016 Sunshine Biopharma Signs Licensing Agreement For Three Additional Generic Products For Treatment Of Cancer And BPH
May 11, 2016 Sunshine Biopharma Signs Licensing Agreement For Anastrozole, The Company's First Generic Drug For Treatment Of Breast Cancer
March 15, 2016 Sunshine Biopharma Eliminates The Debt Obligations Associated With The Recently Acquired Patents For It’s Adva-27a Anticancer Compound
January 20, 2016 Sunshine Biopharma Is Moving Forward With Its Development Plans For Adva-27a Anticancer Compound
December 28, 2015 Sunshine Biopharma Acquires All Remaining Worldwide Patents For Its Adva-27a Anticancer Compound
October 9, 2015 Sunshine Biopharma Acquires The US Patent For Its Anticancer Compound, Adva-27a
August 4, 2015 Sunshine Biopharma Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving The Way For Clinical Trials
May 26, 2015 Sunshine Biopharma To Receive This Week A Sample From The Adva-27a Manufacturing Currently Underway At Lonza In Switzerland
March 24, 2015 Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In India
February 25, 2015 Sunshine Biopharma Announces Change To Its Board Of Directors And Officers
November 19, 2014 Sunshine Biopharma Signs Agreement With Lonza To Manufacture Its Lead Anticancer Compound, Adva-27a
November 3, 2014 Ebola Virus Infections Could Potentially Be Treated With Sunshine Biopharma’s Lead Anticancer Compound, Adva-27a
October 14, 2014 Sunshine Biopharma Retains Renmark Financial Communications To Provide Investor Relations
October 1, 2014 Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Completes The Sop’s Required By Health Canada To Secure Drug Establishment License
September 3, 2014 Sunshine Biopharma Negotiating With Cro’s To Initiate Master Drug File For Adva-27a Anticancer Compound
August 21, 2014 Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Engages Health Canada Specialized Consultants To Secures Pharmaceutical Establishment License
August 11, 2014 Sunshine Biopharma’s Wholly Owned Canadian Subsidiary Secures Dedicated Space To Commence Global Generic Pharmaceutical Operations
June 9, 2014 Sunshine Biopharma's Adva-27a Featured In 2014 Worldwide Uterine Cancer Report For Its Effectiveness Against Multidrug Resistant Uterine Cancer Cells
May 12, 2014 Sunshine Biopharma Announces Issuance Of Notice Of Allowance For The Patent Application Covering Adva-27a Anticancer Compound In Canada
April 29, 2014 Sunshine Biopharma Secures Funding For Its Adva-27a Anticancer Compound From Dutchess Opportunity Fund II
April 7, 2014 Sunshine Biopharma Increases The Effectiveness Of Adva-27a Lead Compound 9.5-fold Against Breast And Pancreatic Cancer In Vitro
March 31, 2014 Management Of Sunshine Biopharma Alarmed By The Recent World Health Organization Report That Cancer Is On The Rise
February 14, 2014 Sunshine Biopharma Begins Construction Of Mouse Xenograft Models For Pancreatic Cancer To Advance Adva-27a As A Treatment For This Deadly Form Of Cancer
June 19, 2013 Sunshine Biopharma’s Anticancer Drug Candidate, Adva-27a, Is Unaffected By The Recent Supreme Court Ruling
June 4, 2013 Sunshine Biopharma Announces That Its Breast Cancer Drug Candidate, Adva-27a, Also Destroys Pancreatic Cancer Cells
May 1, 2013 Sunshine Biopharma Narrows Kilogram Manufacturing Options For Adva-27a Breast Cancer Drug Candidate to Three Suppliers
April 9, 2013 Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations
March 14, 2013 Sunshine Biopharma Commences Negotiations with Contract Manufacturing Organizations for Production of its Multidrug-Resistant Breast Cancer Drug, Adva-27a
February 26, 2013 Sunshine Biopharma Reports on IND Research for its Novel Breast Cancer Drug Candidate, Adva-27a
January 15, 2013 Advanomics Corporation, The Parent Company of Sunshine Biopharma, Files A New Patent Application For Its Multidrug Resistance Adva-27a Anticancer Compound
December 10, 2012 Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found To Be Effective Against Multidrug Resistant Uterine Cancer Cells
December 4, 2012 Sunshine Biopharma Completes Six IND-Enabling Studies for its Anticancer Compound, Adva-27a
November 27, 2012 Advanomics Corporation, The Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents
November 13, 2012 Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a
October 9, 2012 Sunshine Biopharma Receives Scale-Up Manufacturing Protocol For Its Lead Anti-Cancer Compound, Adva-27a
September 25, 2012 Sunshine Biopharma’s Adva-27a Preclinical Research Results to be Published in October Issue of ANTICANCER RESEARCH
September 20, 2012 Breast Cancer News: Geron Drug Fails, Herceptin® May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials
September 13, 2012 Sunshine Biopharma Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, ADva-27a
September 4, 2012 Sunshine Biopharma Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of the Compound's Anti-Cancer Activity
August 15, 2012 Sunshine Biopharama Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal
August 3, 2012 BUYINS.NET Issues Sunshine Biopharma Squeeze Trigger Report
July 30, 3012 Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a
July 24, 2012 Biotech Investor Alert: CFO of Sunshine Biopharma (OTCBB: SBFM) Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a
July 11, 2012 Sunshine Biopharma Engages Beta Pharma Canada For Manufacturing of an Initial Batch of Adva-27a
July 9, 2012 Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB:SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)
July 2, 2012 Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB:SBFM) Discussing its Lead Compound - Adva-27a for Aggressive Forms of Cancer
June 26, 2012 Sunshine Biopharma's Adva-27a Found to be Effective at Killing Multidrug Resistant Lung Cancer Cells
May 22, 2012 Pharmacokinetics Parameters of Sunshine Biopharma's Lead Anti-Cancer Compound Exceed Expectations>
April 9, 2012 Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound
March 26, 2012 Sunshine Biopharma and Binghamton University to Present New Data at the Upcoming American Association for Cancer Research Meeting in Chicago
November 28, 2011 Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals
November 15, 2011 Sunshine Biopharma's Announces Successful Completion of Preclinical Studies for Adva-27a, The Company's Lead Anti-Cancer Compound
October 5, 2011 Sunshine Biopharma's Anti-Cancer Compound, Adva-27a, found to be a Topoisomerase II Inhibitor
August 30, 2011 Clearance of Sunshine Biopharma's Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate
July 27, 2011 Sunshine Biopharma Looking to Mimic Roche's Billion Dollar Cancer Drug Success
July 25, 2011 Sunshine Biopharma's Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism
July 11, 2011 Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells
June 27, 2011 Sunshine Biopharma's Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays
June 17, 2011 Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada
April 1, 2011 Sunshine Biopharma’s CEO Does Live Interview on ChartPoppers.com
March 4, 2011 CEO CFO Interviews Dr. Steve N. Slilaty
February 25, 2011 Interview with Central NY Business Journal
January 26, 2011 FOX 40 WICZ.COM Interview of Binghamton University on Sunshine BioPharma Part 1
January 21, 2011 Sunshine Biopharma And Binghamton University (State University Of New York) Enter Into Research Agreement
October 26, 2010 CEOCAST Interview with Dr. Steve Slilaty of Sunshine BioPharma Inc.
October 13, 2010 Sunshine Biopharma, Inc. Begins Drug Development Activities
October 20, 2009 Mountain West Business Solutions Acquires Sunshine Biopharma